3,4-Diethylbenzenemethanamine | 78813-91-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-Diethylbenzenemethanamine
• 英文别名: (3,4-diethylphenyl)methanamine
• CAS: 78813-91-9
• 化学式: C₁₁H₁₇N
• 分子量: 163.26
• InChiKey: WKOOKCCXYWMLKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Antipruritics
  申请人：Yasui Kiyoshi

  公开号：US20050101590A1

  公开（公告）日：2005-05-12

  It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.

  这意味着它旨在提供止痒药（用于控制瘙痒的药物，抗瘙痒剂和止痒药）。研究发现，具有激动性作用的大麻素受体的化合物具有止痒效果。
• 2-Imino-1,3-thiazine derivatives
  申请人：Hanasaki Koji

  公开号：US20050124617A1

  公开（公告）日：2005-06-09

  The present invention relates to 2-imino-1,3-thiazine derivatives, in specific, 2-imino-1,3-thiazine derivatives having a selective antagonistic activity or agonistic activity to a cannabinoid type 2 receptor and their pharmaceutical use.

  本发明涉及2-亚氨基-1,3-噻嗪衍生物，具体地说，涉及具有针对大麻素2型受体的选择性拮抗活性或激动活性的2-亚氨基-1,3-噻嗪衍生物及其药物用途。
• Medicinal composition containing 1,3-thiazine derivative
  申请人：——

  公开号：US20040116326A1

  公开（公告）日：2004-06-17

  A compound of the formula (I) having a binding activity to the cannabinoid type 2 receptor: 1 wherein R 1 is optionally substituted heterocyclic group or the like; R 2 and R 2 each is independently hydrogen or the like; m is an integer of 0 to 2; A is optionally substituted aromatic carbocyclic group or the like.

  化合物式（I）的一个复合物，具有与大麻素2型受体的结合活性：其中R1是可选择的取代杂环基团或类似物；R2和R2各自独立地为氢或类似物；m是0到2的整数；A是可选择的取代芳香族碳环基团或类似物。
• 2-imino-1,3-thiazine derivatives
  申请人：Hanasaki Koji

  公开号：US20070088020A1

  公开（公告）日：2007-04-19

  The present invention relates to 2-imino-1,3-thiazine derivatives, in specific, 2-imino-1,3-thiazine derivatives having a selective antagonistic activity or agonistic activity to a cannabinoid type 2 receptor and their pharmaceutical use.

  本发明涉及2-亚氨基-1,3-噻嗪衍生物，具体地说，涉及具有选择性拮抗或激动大麻素类型2受体活性的2-亚氨基-1,3-噻嗪衍生物及其药物用途。
• FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS
  申请人：Hangeland Jon J.

  公开号：US20090036438A1

  公开（公告）日：2009-02-05

  The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R 3 , R 4 , R 6 , R 11 , X 1 , X 2 , and X 3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

  本发明提供了一种治疗血栓性或炎症性疾病的方法，该方法向需要治疗的患者施用至少一种公式（I）或公式（V）中的化合物的治疗有效量：或其立体异构体或药学上可接受的盐或溶剂形式，其中变量A、L、Z、R3、R4、R6、R11、X1、X2和X3如本文所定义。公式（I）的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、因子Xa、因子XIa、因子IXa、因子VIIa和/或血浆激肽。特别是，涉及到选择性因子XIa抑制剂的化合物。本发明还提供了公式I范围内的化合物，并涉及包含这些化合物的制药组合物。